Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: A randomized double-blind study

Acta Ophthalmologica

Volumn 90, Issue 1, 2012, Pages 56-60

  Isaac, David Leonardo Cruvinel ^a   Abud, Murilo Batista ^a   Frantz, Kariza Aiko ^a   Rassi, Alan Ricardo ^a   Avila, Marcos ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

bevacizumab; complications from diabetes; diabetic retinopathy; macular oedema therapy; triamcinolone acetonide administration dosage; triamcinolone acetonide therapeutic use; visual acuity

Indexed keywords

BEVACIZUMAB; THERACORT; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETINA MACULA LUTEA; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84856534750     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01817.x     Document Type: Article

References (27)

1. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al,; Pan-American Collaborative Retina Study Group (2007): Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114: 743-750. (Pubitemid 46483714)
2. Beck RW, Edwards AR, Aiello LP, et al,; The Diabetic Retinopathy Clinical Research Network (DRCR.net) (2009): Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 127: 245-251.
3. Early Treatment Diabetic Retinopathy Study Research Group (1985): Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103: 1796-1808.
4. Fang X, Sakaguchi H, Gomi F, et al., (2008): Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol 86: 800-805.
5. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, &, Hori S, (2008): Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110: 1690-1696.
6. Gillies MC, Simpson JM, Billson FA, et al., (2004): Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 122: 336-340. (Pubitemid 38314193)
7. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, &, Zhu M, (2006): Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a doublemasked, placebo-controlled, randomized clinical trial. Ophthalmology 113: 1533-1538. (Pubitemid 44292310)
8. Haritoglou C, Kook D, Neubauer A, et al., (2006): Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26: 999-1005. (Pubitemid 44973218)
9. Jonas JB, Kreissing I, Sofker A, &, Degenring RF, (2003a): Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121: 57-61. (Pubitemid 36401766)
10. Jonas JB, Kreissing I, &, Degenring R, (2003b): Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 87: 24-27. (Pubitemid 36071773)
11. Jonas JB, Degenring R, Kreissig I, &, Akkoyun I, (2004): Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol 138: 1054-1055. (Pubitemid 40040030)
12. Kang SW, Sa HS, Cho HY, &, Kim JI, (2006): Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 124: 653-658.
13. Klein R, Klein BE, Moss SE, Davis MD, &, DeMets DL, (1984): The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetic macular edema. Ophthalmology 91: 1464-1474. (Pubitemid 15197017)
14. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, &, Haritoglou C, (2008): Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 28: 1053-1060.
15. Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, &, Li CL, (2009): Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 29: 292-299.
16. Larsson J, Kifley A, Zhu M, Wang JJ, Mitchell P, Sutter FK, &, Gillies MC, (2009): Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmol 87: 275-280.
17. Maia OO Jr, Takahashi BS, Costa RA, Scott IU, &, Takahashi WY, (2009): Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am J Ophthalmol 147: 291-297.
18. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, &, Baumal C, (2002): Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109: 920-927. (Pubitemid 34465226)
19. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, Caulin C, &, Gaudric A, (2004): Intravitreal Triamcinolone Acetonide for Diabetic Diffuse Macular Edema Preliminary Results of a Prospective Controlled Trial. Ophthalmology 111: 218-225.
20. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, &, Jorge R, (2008): Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular edema. Br J Ophthalmol 92: 76-80.
21. Patel JI, Saleh GM, Hykin PG, Gregor ZJ, &, Cree IA, (2008): Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy. Eye 22: 223-228. (Pubitemid 351266462)
22. Rodrigues EB, Meyer CH, Grumann A Jr, Shiroma H, Aguni JS, &, Farah ME, (2007): Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. Am J Ophthalmol 143: 1035-1037. (Pubitemid 46764639)
23. Saraiva FP, Queiroz MS, Costa PG, Gasparin F, &, Nakashima Y, (2008): Use of intravitreal triamcinolone and laser photocoagulation for the treatment of diffuse diabetic macular edema. Arq Bras Oftalmol 71: 493-498.
24. Scott IU, Edwards AR, Beck RW, et al,; for the Diabetic Retinopathy Clinical Research Network (2007): A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114: 1860-1867.
25. Shimura M, Nakazawa T, Yasuda K, Shiono T, &, Nishida K, (2007): Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular edema. Br J Ophthalmol 91: 449-454. (Pubitemid 46623675)
26. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, &, Nishida K, (2008): Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 145: 854-861.
27. Smithen LM, Ober MD, Maranan L, &, Spaide RF, (2004): Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 138: 740-743. (Pubitemid 39452920)